NDAORALCAPSULE
Approved
Jan 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIDIONE (trimethadione) is an oral small-molecule anticonvulsant approved in 1946 for seizure management. It is an oxazolidinedione class agent with mechanism of action involving seizure threshold elevation. This product represents a legacy therapeutic with limited modern clinical use.
LOE Approaching
With LOE approaching and minimal Part D spending data, this product likely operates as a niche brand with a small commercial team focused on specialist physician relationships rather than broad market development.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and a product in LOE-approaching stage, TRIDIONE offers minimal career growth or advancement opportunity. Roles on this brand are typically maintenance positions suited for early-career specialists in niche therapeutic areas or those seeking stability over expansion.
Brand ManagerField Sales Representative
Worked on TRIDIONE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.